Genetic disease medicine producer BridgeBio Pharma led the carcinoma therapy developer's latest round, having provided an undisclosed amount in December 2016.
PellePharm, a US-based biopharmaceutical company developing treatments for basal cell carcinomas, has closed a $20m series B round led by genetic disease treatment producer BridgeBio Pharma.
The $20m figure represents the round’s third close. BridgeBio Pharma had already provided an undisclosed amount in December 2016 as part of the round, though additional details of that investment have not been disclosed.
Founded in 2012, PellePharm is working on a therapy, named Patidegib, to mitigate basal cell carcinomas, a type of…
